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Summary
The Internet and new communication technologies are
deeply affecting healthcare systems and the provision of
care. The purpose of this article is to evaluate the possib-
ility that cyberhealth, via the development of widespread
easy access to wireless personal computers, tablets and
smartphones, can effectively influence intake of medica-
tion and long-term medication adherence, which is a com-
plex, difficult and dynamic behaviour to adopt and to sus-
tain over time. Because of its novelty, the impact of cyber-
health on drug intake has not yet been well explored. Initial
results have provided some evidence, but more research is
needed to determine the impact of cyberhealth resources on
long-term adherence and health outcomes, its user-friendli-
ness and its adequacy in meeting e-patient needs. The pur-
pose of such Internet-based interventions, which provide
different levels of customisation, is not to take over the
roles of healthcare providers; on the contrary, cyberhealth
platforms should reinforce the alliance between healthcare
providers and patients by filling time-gaps between visits
and allowing patients to upload and/or share feedback ma-
terial to be used during the visits. This shift, however, is not
easily endorsed by healthcare providers, who must master
new eHealth skills, but healthcare systems have a unique
opportunity to invest in the Internet and to use this power-
ful tool to design the future of integrated care. Before this
can occur, however, important issues must be addressed
and resolved, for example ethical considerations, the sci-
entific quality of programmes, reimbursement of activity,
data security and the ownership of uploaded data.
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Introduction
Internet and communication technologies, such as personal
computers, smartphones or tablets, have rapidly and
drastically changed the ways by which human beings com-
municate with each other socially and professionally (e-
mails, social media), as well as the flow of information
(dissemination, quantity and quality of information). Past
boundaries have all but disappeared, and time and geo-
graphy matter increasingly less. All strata of life, including
education and health, have been deeply affected. Accord-
ing to recent estimates, 63% of the population in Europe
uses the Internet [1]. Evidence has shown that healthcare
cannot continue being dissociated from the Internet. Hence,
some journals, such as the Journal of Medical Internet
Research, Telemedicine and eHealth and the International
Journal of Telemedicine and Applications, have begun to
address this topic.
Healthcare professionals know how much the Internet has
positively changed their activities regarding, for example,
knowledge (open access to medical journals, medical
guidelines and online conferences) or professional net-
working (for continuing education and sharing professional
experiences, crowdsourcing* for sharing and solving prob-
lems). (*Jeff Howe defined the neologism crowdsourcing
in 2006 in Wired Magazine as “a process that involves out-
sourcing tasks to a distributed, undefined and large net-
work of people in the form of an open call through the
internet’ with the aim, for example, of generating know-
ledge”.) Healthcare professionals use what is relevant to
their own activities, which implies that they are able to de-
velop specific abilities to ensure the usefulness and qual-
ity of data while regulating its flow and storage (also called
digital curation). In a similar fashion, the Internet is def-
initely changing patients’ attitudes toward health manage-
ment.
The World Health Organization (WHO) defines eHealth as
the transfer of health resources and health care by electron-
ic means [2]. Cyberhealth is defined as the provision of
care through the Internet [3]. More specifically, health 2.0
is the use of a specific set of Internet tools (such as blogs,
podcasts and tagging searches) by healthcare providers and
patients, who together use open sources to generate inform-
ation, collaborate, promote health education and personal-
ise healthcare [4]. Thanks to the Internet era, medical in-
formation is more readily available than it used to be. The
Internet is powerful, but it can also be risky, as its informa-
tion might be biased or even false. Healthcare professionals
often complain about the poor quality of information pa-
tients get on the Internet related to their health state, dis-
ease or treatment options. Either the quality of informa-
tion is poor, or the information does not make sense; thus,
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often patients have a hard time making an informed de-
cision, especially when their health literacy is low [5]. At
the same time, e-patients (also known as Internet patients)
are increasingly active participants in their care and re-
port increasingly accurate health information and a more
autonomous – but not always improved – relationship with
their healthcare providers [6].
Cyberhealth and drug intake
Computer- and now Internet-tailored strategies have be-
come common and efficient for altering certain health-risk
behaviours, for example smoking [7]. However, thus far
some results have been controversial and inconclusive, for
example regarding changing dietary behaviours [8]. Based
on this fact, the potential of Internet strategies must be con-
sidered for altering and supporting drug intake behaviour
during long-term treatments, such as human immunodefi-
ciency virus (HIV) infection, cancer, cardiovascular dis-
eases, asthma or epilepsy. The present work tries to eval-
uate the possibility that cyberhealth, via the development
of population-wide easy access to wireless personal com-
puters, tablets and smartphones, can effectively influence
the intake of medication and long-term medication adher-
ence.
Worldwide, the interactions between patients and health-
care professionals have evolved during the last two decades
towards a more balanced partnership. An increasing num-
ber of patients participate in their own medical decisions.
Health literacy and patient empowerment support the pa-
tients’ abilities and competencies in engaging with this
relationship. Supporting the self-management of medica-
tion intake implies person-centred interventions, and the
Internet could represent a powerful technology for embra-
cing this new orientation in care. However, the impact of
providing such intervention through the Internet must be
assessed to determine whether it is effective in improving
autonomous and safe intake of medication.
As a fundamental prerequisite, it seems obvious that cyber-
health cannot replace the continuous interprofessional col-
laboration among patients, physicians, pharmacists, nurses
and other healthcare providers. However, thanks to its at-
tempts at a constructive human relationship, cyberhealth
could become an interesting facilitator to meet patients’
needs during the time between visits with the healthcare
providers. However, healthcare providers, as well as pa-
tients, must master new complex skills and specific com-
petences, called eHealth Literacy 2.0, to integrate cyber-
health into their relationship and to benefit from its poten-
tial use [9, 10].
Why would it be important to explore
the effectiveness of cyberhealth to
support the intake of drugs?
The intake of medication and specifically medication ad-
herence are dynamic and complex human behaviours that
are influenced by many factors (see fig. 1). Some factors
relate to the healthcare system and how much it addresses
and supports patient adherence. The prevalence and con-
sequences of nonadherence affect the quality of care, and
there is an urgent need to develop effective intervention
programs to support the responsible and safe use of medic-
ation.
Epidemiology of nonadherence in
patients with chronic diseases
There is a popular phrase summing up nonadherence:
"Drugs don’t work if patients don’t take them". In 2003,
the WHO published a report recognising the poor adher-
ence to chronic disease treatments as a worldwide problem
of striking magnitude. Nevertheless, the evaluation of the
prevalence of nonadherence is inherently susceptible to bi-
as, as it relies on the quality of measurement as well as
the chosen cut-offs (adherence vs nonadherence) [11, 12].
However, the WHO estimates that 50% of patients in deve-
loped as well as developing countries are nonadherent. The
number of nonadherent patients is expected to grow over
the coming years as the burden of chronic disease grows
worldwide [13]. Blaschke mentioned that a mean of 60%
of patients were still adherent 1 year after having started
a chronic therapy [14]. As well, Briesacher reported that
72% of patients treated for hypertension, 68% for hypo-
thyroidism, 65% for type 2 diabetes, 61% for seizure disor-
ders, 55% for hypercholesterolaemia, 51% for osteoporos-
is and 37% for gout still took their medicine at the 1-year
follow-up [15].
Recently, the ABC expert team* has reviewed the tax-
onomy defining adherence to medication. (*The ABC Pro-
ject aimed to produce evidence-based recommendations
for European policymakers to improve patient adherence
and thereby promote more efficient use of medicines. The
ABC team is a collaboration of experts from the Medical
University of Lodz, Poland, Bangor University, UK,
AARDEX Group, Switzerland,Keele University, UK an-
dKatholieke Universiteit Leuven, Belgium.) They define it
as “the process by which patients take their medications
as prescribed, composed of initiation, implementation and
discontinuation. Persistence is the length of time between
initiation and the last dose, which immediately precedes
discontinuation” [12]. Medication adherence has been re-
cognised as a dynamic process that is influenced not only
by the patient but also by significant others, prescribers,
providers, community, institutions and healthcare policies
[16]. Different determinants of medication adherence have
been described. The WHO proposed a five-dimension clas-
sification system composed of socioeconomic factors,
healthcare team- and system-related factors, condition-re-
lated factors, therapy-related factors and patient-related
factors (fig. 1) [13]. A recent systematic review identified
771 individual determinants of patient nonadherence across
all the dimensions of the classification. Patients’ attitudes
and beliefs appear to be the factors most closely associated
with nonadherence [12]. Osterberg outlines the major pre-
dictors of poor adherence as psychological problems, cog-
nitive impairments, treatment of asymptomatic diseases,
inadequate follow-up planning, treatment side effects, pa-
tient’s lack of belief in the benefit of treatment, patient’s
lack of insight into the illness, poor provider-patient rela-
tionships, practical and economic barriers to care or med-
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ication, missed appointments and the complexity of treat-
ment [17].
Adherence fades with time for different reasons (lack of
priority, fear of long-term use, pill fatigue, lack of personal
benefit, little feedback from the prescriber, etc.). The tim-
ing of the intake becomes more erratic, and dose omissions
occur more frequently. However, adherence frequently im-
proves just before or after a medical appointment [17]. The
consequences of nonadherence vary from major to trivi-
al, spanning its effects on pharmacodynamic and pharma-
cokinetic parameters, as well as its short- and long-term ef-
fects on the disease [18].
Increasing and sustaining individually regulated drug man-
agement and medication adherence over time are difficult
tasks. The need for efficient interventions is increasing
along with newly complex and costly long-term treatments
and the increasing number of long-term and aging patients.
Costs of nonadherence and costs of
interventions to support adherence in
patients with chronic diseases
The following was one of the take-home messages of the
2003 report of the WHO: “the consequences of poor ad-
herence to long-term therapies are poor health outcomes
and increased health care costs” [13]. We can evaluate the
potential impact of nonadherence knowing that fewer than
25% of hypertensive patients achieve optimum blood pres-
sure [13] and that, as shown by Burnier et al., 50% of
nonresponders were in fact nonadherent [19]. In the USA,
more than 100 billion US-dollars a year are spent on hos-
pitalisations due to poor adherence [20]. In diabetes, a 10%
increase in medication possession ratio was associated with
an 8.6% decrease of global annual healthcare costs [21,
22]. Similarly, in schizophrenia, a 10% increase in this ra-
tio was associated with a 12.6% decrease of semiannual
healthcare costs [23, 24]. Hopefully, these reported out-
comes will motivate researchers and healthcare providers
to request that governments and insurers support new, data-
driven medication adherence programmes.
Nonadherence could lead to failed treatment, poor clinical
outcomes, misdiagnosis, inappropriate dose escalation,
Figure 1
The five dimensions of adherence (reproduced with the permission
of the WHO from Sabaté E (2003) [13]).
emergence of drug resistance, rebounding or recurrent first-
dose effects, increasing hospitalisation and practitioner vis-
its, and a poorer quality of life. At a societal level, nonad-
herence may cause deleterious consequences for workforce
productivity and the transmission of infectious diseases.
These factors can bias the efficacy of clinical studies or ad-
versely affect the results of the drug, ultimately influencing
healthcare policy [17, 25–27]. The WHO and the Institute
of Healthcare Informatics estimate that nonadherence con-
tributes to 57% of the world’s total avoidable cost due to
suboptimal medicine use [28].
Roebuck questioned why, given the widespread debate
over healthcare costs, medication adherence in patients
with chronic diseases does not feature more prominently in
these discussions. He recognises that “research into medic-
ation compliance (adherence) suffers from methodologic-
al challenges that may call the validity of the results into
question” [29].
In a recent systematic review on the cost-effectiveness of
adherence-enhancing interventions, the ABC project team
underlined the paucity of evidence and the need for more
and better research. Their work is based on Elliott’s review
in 2005 [30], updated by the UK National Institute for
Health and Care Excellence (NICE) in 2009 [31]. They
were not able to draw conclusions because of study hetero-
geneity [12].
Can cyberhealth support drug intake?
Evidence from the literature
To change a suboptimal adherence behaviour to more per-
sistent and accurate drug intake behaviours, the patient
must be involved in the decision-making process. To fully
engage in such a process, patients also require both time
and sound theory-based interventions to be conventionally
transmitted by educated healthcare providers. However,
web-based interventions could play an increasing role in
changing patient behaviours by sustaining the healthcare
provider’s messages, providing continuous monitoring and
building collective intelligence.
During the last decade, the number of websites allowing
patients to manage medical information has increased, for
example a number of sites allow diabetic patients to upload
sugar levels. Lately, more complex websites are emerging
that allow patients to upload and/or share additional in-
formation such as personal and medical information.
Because of its novelty, the impact of cyberhealth on drug
intake has not yet been well explored. However, early res-
ults have provided some evidence. Linn et al. published a
systematic review on effects of cyberhealth interventions
on medication adherence. Thirteen studies met the inclu-
sion criteria. They found that 11 (85%) studies showed a
moderate to significant impact from Internet interventions
on adherence to treatment. Evidence came especially from
three studies of good quality, the main results of which are
as follows. Joseph et al. showed in a randomised clinical
trial (RCT) that, compared with generic asthma websites,
a web-based, 6-month tailored approach to changing neg-
ative asthma behaviours was effective and economical in
improving asthma outcomes at 12 months in the hard-to-
reach African-American teenage population. Notably, ac-
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cess to the Internet was provided through school computers
[32]. DeVito et al. showed in a pilot RCT conducted in the
USA that lung transplant patients using an electronic pock-
et device were, compared with standard care protocols,
more engaged in self-care behaviours for the first 2 months
after hospital discharge [33]. Unfortunately, long-term res-
ults are unavailable. Jan showed that a Taiwanese Internet-
based asthma telemonitoring programme increased chil-
dren’s and caregivers’ self-management skills at 12 weeks
and decreased negative clinical outcomes compared with
standard care protocols [34]. However, long-term results
are also lacking. Obviously, more research is needed to
confirm these early results.
The number of available Internet websites is increasing, in-
cluding webEase in Epilepsia [35], Puff City in Asthma
[36] and prochange behaviour systems, a generic website
for long-term patients [37]. Such interactive websites
provide several levels of intervention programmes on drug
intake, including the following: (1) basic one-way drug in-
formation and education on drug use to increase patient
knowledge; (2) encouragement to upload personal data and
self-monitor one’s own drug intake and clinical data; and
(3) tailored web-based interventions and individualised
feedback, depending on the patient’s profile, health, be-
liefs, attitudes, barriers and needs, all of which are assessed
online. Typically assessed dimensions include symptoms,
control of disease, medication use (name of medication,
dosage and frequency of use), knowledge, motivation, self-
efficacy, self-regulatory strategies, goals, social support,
mental health, frequency of medical visits, emergency vis-
its and hospitalisations.
Moreover, importantly, recent literature on adherence has
shown that interventions providing feedback to patients on
their recent drug intake enhances patient adherence [38,
39]. Internet programmes could provide such individual
feedback with suitable, personalised timing. However, the
literature is not yet conclusive on the relation between the
extent of customisation and the impact on medication be-
haviours [7, 40]. It also seems that frequency of using the
interactive website is determinant [40].
Little is known about the profiles of patients who could be-
nefit from such cyberhealth programmes. Intuitively, teen-
agers seem to be likely targets, as they are both frequent
Internet users and difficult to retain in care. Indeed, many
teenagers with chronic diseases are reluctant to visit their
healthcare providers on a regular basis [41]. The Internet
could also be useful for long-term patients living in remote,
isolated areas or for frequent travellers. Unfortunately, we
do not know yet whether online benefits apply mostly to
new patients engaging in new treatments, experienced pa-
tients, or both. We also lack information on the relevant de-
terminants of the level of health literacy and eHealth Liter-
acy 2.0.
The methods used to measure adherence in studies that
have evaluated the impact of cyberhealth on drug intake
or drug management were often poor and relied mostly on
patient self-reports. However, electronic pill containers are
now available to monitor and support patient adherence
[38]. Reading of such devices could be performed remotely
instead of at a pharmacy visit. The frequency of these re-
mote readings can be scheduled according to patient needs,
and healthcare providers could intervene promptly in the
case of a cluster of unusual drug omissions [42]. Patients
and their caregivers could benefit from such a monitoring
system, which could reinforce the alliance between the pa-
tient encountering major issues with drug intake and the
healthcare system.
Preliminary results have also shown that the effects of these
programmes decrease after their termination, which is con-
sistent with most traditional interventions as well [7]. There
is a need to develop tailored programmes that could be
used iteratively over time according to a patient’s evolving
needs. Such needs have to be identified and discussed with
healthcare providers.
Main potential benefits of cyberhealth
Such web-based and easily accessible programmes aim at
promoting self-care management by involving patients in
active care and hence by giving them new means to play a
major role in managing their own health (e-patients). Web-
based programmes could bridge a time-gap and give pa-
tients a chance of interaction during daily life, in parallel
with chronic medication intake. They provide the unique
opportunity to integrate health and social care by guiding
patients in their own thinking, decisions and action plan,
by identifying their individual needs, by giving up-to-date
information and by empowering them to discuss openly
their unsolved issues with their healthcare providers. Ac-
cessing information in an iterative way and combining di-
verse media (written information, audio and video) can also
enhance the patient’s memorisation process. Patients could
gain control over their disease, which should be beneficial
to their quality of life.
Tailored messages and customised health programmes, in
which patients can choose which the components they
would like to use, are theoretically more adapted to pa-
tients’ needs. They have the potential for supporting pa-
tients in changing behaviours and attitudes towards an im-
proved intake of medication in the long term with increased
relevance and depth of support [7]. In fact, web-based pro-
grammes are less biased by the patient’s memory recall is-
sues than standard care, provided relevant data are updated
on a regular basis. They might also enhance the patient’s
awareness of personal attitudes, and clarify misconceptions
or misunderstandings.
Patients can upload in real time information on the way
they deal with their treatment on daily basis (for example,
date of clinical event, date and time of a missed dose and
circumstances when the dose was missed), consult and get
feedback as visual graphs of uploaded data, and explore
changes over time on their own, or with their family or
healthcare giver. Indeed, feedback generates sustained mo-
tivation and cements a positive drug intake habit [38, 39].
For example, on www.webease.org, epileptic patients can
upload self-reported data on their medication-taking beha-
viour over the last 3 days, including how many prescribed
doses were missed. Patients may then generate graphs con-
necting, for example, medication adherence to seizures.
Insights gained by such visualisations may motivate pa-
tients to be more adherent.
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Furthermore, when linked to empathic follow-ups with
healthcare providers, such programmes are likely to pro-
mote the emergence of novel, patient-friendly solutions.
For example, a patient could benefit from filling out a self-
efficacy scale when experiencing the first symptoms of pill
fatigue; when detecting pill fatigue, the programme should
engage the patient in scheduling a new appointment with
his or her healthcare provider, who could be the patient’s
physician or pharmacist. The same could happen when
side-effects emerge or worsen (using an online pain ana-
logue scale); the programme should recommend that the
patient contacts his or her physician.
Hence, the purpose of such Internet programmes is not to
take over the role of healthcare givers. On the contrary,
they should reinforce provider’s messages, maintain access
to tailored information during the time between medical
visits and encourage patients to disclose their treatment is-
sues to healthcare providers. The alliance between the pa-
tient and the healthcare providers has to benefit from it [43,
44]. Quality of communication and assessment of the pa-
tient’s needs might be enhanced through the right integ-
ration of cyberhealth into clinical practice. If cyberhealth
adequately addresses e-patients’ needs, it could drive im-
proved continuity of care.
In sum, to get full benefit out of such personal self-admin-
istered health records, data should be shared with health-
care providers. Patients and healthcare providers must
agree on: (1) the material they would like to exchange and
discuss, and (2) the frequency and means by which this ex-
change can be made most effectively. For example, the pro-
vider has to intervene when data have worsened [45]. In
such a case, an alarm should encourage the patient to visit
healthcare providers soon.
Dilemmas and potential risks of
cyberhealth
Importantly, the potential benefits of Cyberhealth must be
balanced against its risks (table 1). Although interactive
tools and collaborative software permit a new orientation
to clinical care, there is no one solution that fits everyone;
thus, such programmes should apply to patients willing and
with the skills to use them. These programmes should be
adapted to the age, culture, language (most of them are
available in English only), needs and social levels of the
targeted populations, and they should be kept up-to-date.
Their content must be theory-based and independent and
should reflect evidence-based practices. Functionality and
usability are as important as content and must be just as
well-tested [43]. Monitoring the attrition rate should show
whether patients persist in using cyberhealth, which is an
important quality measure of the programme. If patients
lack interest in a cyberhealth programme, they will not be-
nefit from it; thus, the healthcare provider must adapt care
accordingly.
We cannot dismiss the risk that cyberhealth could keep
patients away from healthcare providers, increasing their
distance and decreasing their quality of care. With this in
mind, healthcare providers could better adjust care to pa-
tients’ needs by using the feedback provided by cyber-
health to discuss empathically relevant determinants of
medication intake during in-person appointments. We
should also keep in mind that this system may create a risk
of fostering inequalities in healthcare between those who
can access the Internet and those who cannot, through lack
of skill with or availability of technology (risk of a digital
divide). Thus, adjustment to the needs of a patient or a pop-
ulation is important (for example, using school computers
for teenagers).
We also need more data on the cost-effectiveness and ap-
plicability to standard care of such cyberhealth pro-
grammes to create financial models and determine whether
public health funding should support such developments.
Additionally, ethical considerations should pave the way
for successful implementations. One must also think of
a competent authority to control the scientific quality of
the content of such programmes and their user-friendliness
(Health On the Net Foundation [HON] and others). Finally,
health authorities must also devise methods through which
healthcare providers will be reimbursed for integrating
these tools into their practice [3].
Table 1: Examples of potential benefits and risks of cyberhealth in supporting the intake of medication.
Potential benefits Potential risks
Empowerment of patients by giving them new means to play a major role in managing their own
health
Enhanced assessment of patient’s needs in real time
Sustained healthcare provider’s messages, provision of continuous monitoring and bridging of the
time-gap between scheduled visits with providers
Promotion of the “e-patient” concept: enhancement of a 24-hours-a-day, multidirectional flow of
information (patient-healthcare providers-online communities)
Decrease in the patient’s feeling of isolation Capacity to reach patients who are difficult to retain in
care (e.g. teenagers, or socially or geographically isolated patients)
Provision of tailored interventions and individualised feedback to sustain patient’s motivation
(person-centred care)
Provision of up-to-date information; increase in patient knowledge on responsible use of medicines
Capacity to trigger adapted alarm messages in case situation worsens and facilitated relationship
with healthcare providers
Poor control of quality of websites content (evidence- and theory-
based, independency)
Lack of customisation of websites (lack of adaptation to age, culture,
language, computer skills, health literacy, etc.)
Keeping patients away from healthcare providers
Lack of uptake and insufficient frequency of use by patients in daily
life
Lack of patients and healthcare providers’ readiness and e-Health
literacy 2.0
Fostering inequalities in healthcare (digital divide)
Confidentiality and patient data use issues
Cost and reimbursement issues
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Cyberhealth programmes must be confidential and secure,
especially when patients upload personal data on their drug
intake. Healthcare authorities must take responsibility for
insuring the appropriate storage of personal data, according
to national laws and local institutional requirements [45].
They must also regulate the scientific and commercial
properties of uploaded data, as the richness of such avail-
able data represents a substantial new opportunity for re-
search.
Well-designed studies will be needed to assess the effect-
iveness of these comprehensive websites when integrated
into practice by both patients and their healthcare pro-
viders. Furthermore, identifying the factors likely to drive
the acceptance and adoption of these sites by both patients
and healthcare providers will be key to their success.
Conclusion and perspectives
Cyberhealth is already undoubtedly modifying healthcare
and long-term patient follow-up. Although cyberhealth
seems to represent a promising method of supporting pa-
tient drug intake, we need more evidence to determine its
(cost-) effectiveness and feasibility. Ultimately, we must
determine the impact of cyberhealth tools on long-term ad-
herence and health outcomes. Further research is required
to evaluate strategies for the integration of cyberhealth pro-
grammes into clinical practice in order to avoid major pit-
falls. This represents a huge shift that can be difficult to
manage for healthcare systems; however, the potential op-
portunities are inescapable. One benefit is to move with pa-
tients into the Internet world instead of stranding patients in
a web of misinformation on their own. Entering this gener-
ation of digital humanity, healthcare cannot stay on the side
any longer [46]. Therefore, we urgently need high-quality
research that promotes the safe use of cyberhealth to foster
safe, efficient and economical drug intake. Aside from drug
intake, cyberhealth comprehensive care management pro-
grammes should monitor simultaneously a series of health
behaviours, such as smoking, alcohol consumption, weight
loss and physical exercise. In this sense, cyberhealth might
facilitate better integrated care in the future.
Last but not least, crowd-sourced cohorts on drug intake
represent a new reservoir of research data alongside insti-
tutional research. These cohorts have the potential to com-
plement traditional research and generate new data on pa-
tients’ habits and needs regarding drugs [45].
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Figures (large format)
Figure 1
The five dimensions of adherence (reproduced with the permission of the WHO from Sabaté E (2003) [13]).
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